Nektar Therapeutics (NKTR) Total Current Liabilities (2010 - 2026)
Nektar Therapeutics (NKTR) posted quarterly Total Current Liabilities of $57.7 million for Q1 2026, down 18.64% year-over-year from $70.9 million in Q1 2025, and up 7.79% quarter-over-quarter from $53.5 million in Q4 2025.
Nektar Therapeutics (NKTR) Total Current Liabilities (2010 - 2026) Analysis & Trends
Nektar Therapeutics' Total Current Liabilities history runs 17 years deep, the most recent figure standing at $57.7 million for Q1 2026.
- In Q1 2026, Total Current Liabilities fell 18.64% year-over-year to $57.7 million; the TTM figure through Mar 2026 stood at $57.7 million (down 18.64% YoY), while the FY2025 annual figure was $53.5 million, down 12.81% from the prior year.
- Total Current Liabilities for Q1 2026 stood at $57.7 million, up from $53.5 million in the prior quarter.
- The five-year high for Total Current Liabilities was $105.3 million in Q1 2022, with the low at $50.7 million in Q2 2023.
- The 5-year median for Total Current Liabilities is $61.4 million (2024), against an average of $66.8 million.
- The sharpest annual moves came in 2023 and 2025: Total Current Liabilities sank 51.71% in 2023, then soared 35.35% in 2025.
- Nektar Therapeutics' Total Current Liabilities stood at $68.2 million in 2022, then dropped by 24.83% to $51.3 million in 2023, then grew by 19.76% to $61.4 million in 2024, then slipped by 12.81% to $53.5 million in 2025, then increased by 7.79% to $57.7 million in 2026.
- Business Quant data shows NKTR's Total Current Liabilities at $57.7 million in Q1 2026, $53.5 million in Q4 2025, and $66.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Nektar Therapeutics | 1.49 Bn | 919.46 Mn | 3.16 Mn | 57.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 57.71 Mn |
| Dec 31, 2025 | 53.54 Mn |
| Sep 30, 2025 | 66.34 Mn |
| Jun 30, 2025 | 71.39 Mn |
| Mar 31, 2025 | 70.93 Mn |
| Dec 31, 2024 | 61.40 Mn |
| Sep 30, 2024 | 67.58 Mn |
| Jun 30, 2024 | 57.33 Mn |
| Mar 31, 2024 | 52.41 Mn |
| Dec 31, 2023 | 51.27 Mn |
| Sep 30, 2023 | 52.11 Mn |
| Jun 30, 2023 | 50.69 Mn |
| Mar 31, 2023 | 59.88 Mn |
| Dec 31, 2022 | 68.20 Mn |
| Sep 30, 2022 | 83.99 Mn |
| Jun 30, 2022 | 104.99 Mn |
| Mar 31, 2022 | 105.28 Mn |
| Dec 31, 2021 | 85.20 Mn |
| Sep 30, 2021 | 139.97 Mn |
| Jun 30, 2021 | 131.02 Mn |